Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

154 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Khubchandani S, et al. Among authors: czuczman ms. Curr Opin Investig Drugs. 2009 Jun;10(6):579-87. Curr Opin Investig Drugs. 2009. PMID: 19513947
Use of rituximab, the new FDA-approved antibody.
Leget GA, Czuczman MS. Leget GA, et al. Among authors: czuczman ms. Curr Opin Oncol. 1998 Nov;10(6):548-51. doi: 10.1097/00001622-199811000-00012. Curr Opin Oncol. 1998. PMID: 9818234 Review.
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Czuczman MS, et al. Blood. 1999 Jun 1;93(11):3931-9. Blood. 1999. PMID: 10339502
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Czuczman MS, et al. J Clin Oncol. 1999 Jan;17(1):268-76. doi: 10.1200/JCO.1999.17.1.268. J Clin Oncol. 1999. PMID: 10458242 Clinical Trial.
CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
Czuczman MS. Czuczman MS. Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96. Semin Oncol. 1999. PMID: 10561023 Clinical Trial.
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Czuczman MS, Grillo-López AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney D. Czuczman MS, et al. Ann Oncol. 2001 Jan;12(1):109-14. doi: 10.1023/a:1008395214584. Ann Oncol. 2001. PMID: 11249036 Clinical Trial.
A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. Khorana A, et al. Among authors: czuczman ms. Leuk Lymphoma. 2001 Mar;41(1-2):77-87. doi: 10.3109/10428190109057956. Leuk Lymphoma. 2001. PMID: 11342359 Clinical Trial.
Combination chemotherapy and rituximab.
Czuczman MS. Czuczman MS. Anticancer Drugs. 2001 Jun;12 Suppl 2:S15-9. Anticancer Drugs. 2001. PMID: 11508932 Review.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Czuczman MS, et al. Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40. Semin Oncol. 2002. PMID: 11842387 Review.
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Czuczman MS. Czuczman MS. Semin Oncol. 2002 Apr;29(2 Suppl 6):11-7. doi: 10.1053/sonc.2002.32748. Semin Oncol. 2002. PMID: 12040529 Review.
154 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback